The use of BCR and CHK inhibitors or dasatinib lacked cooperative combination activity (51–89% median viability in combination vs. 53–86% for AZD7762 alone, 50–83% in combination vs. 48-81% for dasatinib alone, 46–102% in combination vs. 42–109% for PF477736 alone), suggesting that the activity of all these inhibitors in CLL derives from already maximal BCR component inhibition (Fig. 6b). The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.